甲状腺结节基因融合的临床意义与恶性风险
该回顾性研究纳入2010至2024年MSKCC接受ThyroSeq检测并手术的1035例患者,131个结节携带基因融合。细胞学不确定结节中孤立融合总体恶性风险75.5%,高风险癌风险6.6%;BRAF样融合恶性风险88.9%,RAS样69.5%,中性融合86.4%。融合阳性不等同于侵袭性疾病。
要点
- 细胞学不确定甲状腺结节中基因融合总体恶性风险75.5%,高风险癌仅6.6%。
- BRAF样融合恶性风险88.9%高于RAS样69.5%,但高风险癌率均低。
- 融合阳性不应单独视为侵袭性疾病,需结合细胞学、影像和临床特征决策。
核心结论
- 细胞学不确定甲状腺结节中基因融合与高恶性风险相关,但ATA高风险癌患病率低。
- 融合阳性本身不应等同于侵袭性疾病。
- 决定初始手术范围时应整合分子结果与细胞学、影像和临床特征。
研究设计与样本
- 回顾性识别2010至2024年在Memorial Sloan Kettering Cancer Center接受甲状腺细针穿刺ThyroSeq检测并随后甲状腺切除术的患者。
- 共1035例患者有术前ThyroSeq数据,131个结节携带基因融合。
- 融合分为BRAF样18例、RAS样72例、中性41例;3例合并突变被排除于恶性风险计算。
主要发现
- 全队列中良性或低风险肿瘤24例,低或中风险癌85例,高风险癌19例。
- 细胞学不确定结节中孤立基因融合总体恶性风险75.5%,高风险癌风险6.6%。
- BRAF样融合恶性风险88.9%、高风险癌11.1%;RAS样为69.5%和6.7%;中性融合为86.4%和4.5%。
- 中位随访44.4个月,2例复发,无甲状腺癌相关死亡。
关键数值与推荐
- 根据2025年美国甲状腺协会风险标准,将组织病理学结局分为良性/低风险肿瘤、低或中风险癌、高风险癌。
临床怎么用
- 对细胞学不确定且检出基因融合的甲状腺结节,应认识到总体恶性风险高但高风险癌比例低。
- 不应仅凭融合阳性判定为侵袭性疾病,需结合细胞学、影像和临床特征综合评估。
- 初始手术范围的确定应整合分子检测结果与细胞学、影像及临床特征。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Gene fusions are increasingly identified during molecular testing of cytologically indeterminate thyroid nodules, but their associated risk of malignancy and risk of clinically high-risk carcinoma remain incompletely defined. This study evaluated the clinicopathologic significance of gene fusions detected by preoperative ThyroSeq testing, with emphasis on risk stratification by fusion class. METHODS: Patients undergoing thyroid fine-needle aspiration with ThyroSeq testing followed by thyroidectomy at the Memorial Sloan Kettering Cancer Center between 2010 and 2024 were retrospectively identified. Nodules harboring gene fusions were categorized as BRAF-like, RAS-like, or neutral fusions. Surgical pathology was reviewed by subspecialty endocrine pathologists. Histopathologic outcomes were classified as benign/low-risk neoplasms, low- or intermediate-risk carcinomas, or high-risk carcinomas according to 2025 American Thyroid Association risk criteria. Risk of malignancy and risk of high-risk carcinoma were calculated for cytologically indeterminate nodules. RESULTS: Among 1,035 patients with available preoperative ThyroSeq data, 131 nodules harbored a gene fusion. BRAF-like, RAS-like, and neutral fusions accounted for 18, 72, and 41 cases, respectively. Three cases with concurrent mutations were excluded from risk-of-malignancy calculations. In the full cohort, benign or low-risk neoplasms were identified in 24 cases, low- or intermediate-risk carcinomas in 85 cases, and high-risk carcinomas in 19 cases. Among cytologically indeterminate nodules with isolated gene fusions, the overall risk of malignancy was 75.5%, whereas the risk of high-risk carcinoma was 6.6%. BRAF-like fusions had a risk of malignancy of 88.9% and a high-risk carcinoma rate of 11.1%; RAS-like fusions had corresponding rates of 69.5% and 6.7%; and neutral fusions had rates of 86.4% and 4.5%. During a median follow-up of 44.4 months, 2 recurrences occurred, with no thyroid cancer-related deaths. CONCLUSION: Gene fusions in cytologically indeterminate thyroid nodules are associated with a high risk of malignancy but a low prevalence of American Thyroid Association high-risk carcinoma. Fusion positivity alone should not be equated with aggressive disease. These findings support integrating molecular results with cytologic, radiologic, and clinical features when determining the extent of initial surgery.
引用
- Hintze JM, Auger S, Instrum R, et al. Clinical significance and risk of malignancy of thyroid nodules harboring gene fusions. Surgery. 2026. PMID: 42962455. doi:10.1016/j.surg.2026.110675
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。